{"id":102125,"name":"MALLINCKRODT","slug":"mallinckrodt","state":"MO","country":"United States of America","description":"Specialty Pharmaceutical Company","totalSpending":1330000,"filings":32,"yearlySpending":[{"year":2018,"income":160000},{"year":2019,"income":160000},{"year":2020,"income":160000},{"year":2021,"income":200000},{"year":2022,"income":160000},{"year":2023,"income":190000},{"year":2024,"income":200000},{"year":2025,"income":100000}],"issues":[{"code":"TAX","display":"Taxation/Internal Revenue Code"},{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["ALPINE GROUP PARTNERS, LLC."],"lobbyists":["COURTNEY JOHNSON","KEENAN AUSTIN REED"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Tax Reform","Legislation related to drug pricing\nLegislation related to opioids\nH.R. 5080;\nH.R. 5083","Legislation related to drug pricing","Tax Reform","Legislation related to drug pricing\nLegislation related to opioids\nH.R. 5080;\nH.R. 5083\nS. 2875"]}